Moderna Shares Plummet After FDA Rejects Flu Vaccine Application

The FDA has rejected Moderna's flu vaccine application, leading to a nearly 10% drop in the company's stock. Moderna's financial health shows challenges with negative margins and declining revenue growth. Valuation metrics suggest the stock is significantly overvalued, with a high level of volatility. The company's operating margin is -157.27% and net margin is -141.51%, indicating substantial operational and net losses.